---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-032540"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T07:58:16.528250+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CervoMed to present RewinD-LB Phase 2b data at ILBDC Jan 2025; topline due Dec 2024

## Summary
- Oral presentation of detailed safety/efficacy results from neflamapimod Phase 2b in DLB at ILBDC on Jan 31, 2025.
- Topline results from RewinD-LB Phase 2b trial expected to be disclosed in December 2024.
- CEO expresses confidence in trial design to detect statistically significant and clinically meaningful difference.
- Baseline patient characteristics from RewinD-LB to be presented at CTAD conference.
- No approved therapies for DLB; neflamapimod aims to address this unmet need.

## SEC filing metadata
- accession: 0001437749-24-032540
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774924032540/0001437749-24-032540-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774924032540/crvo20241030_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-032540
- JSON: https://secwatch.observer/filing/0001437749-24-032540.json
- Plain text: https://secwatch.observer/filing/0001437749-24-032540.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.